IRIS
MILANESE, MARCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 19.320
AS - Asia 48
SA - Sud America 10
NA - Nord America 2
Totale 19.380
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 19.320
CN - Cina 34
BR - Brasile 9
SG - Singapore 5
VN - Vietnam 5
ID - Indonesia 2
US - Stati Uniti d'America 2
AR - Argentina 1
BD - Bangladesh 1
HK - Hong Kong 1
Totale 19.380
Salva come PNG Salva come JPEG
Città #
Genova 9.343
Genoa 6.760
Vado Ligure 1.683
Rapallo 1.492
Bordighera 40
Beijing 15
Singapore 5
Ashburn 2
Hanoi 2
Alegre 1
Barra do Corda 1
Buenos Aires 1
Campos dos Goytacazes 1
Ho Chi Minh City 1
Hong Kong 1
Mariana 1
Milan 1
Nam Định 1
Pekanbaru 1
Rio de Janeiro 1
Santo Antônio da Patrulha 1
Thái Bình 1
Trindade 1
Três Barras do Paraná 1
Turin 1
Valparaíso de Goiás 1
Totale 19.359
Salva come PNG Salva come JPEG
Nome #
Acute stress increases depolarization-evoked glutamate release and presynaptic SNARE complex accumulation in prefrontal/frontal cortex. The dampening action of antidepressants. 211
In-vivo effects of knocking-down metabotropic glutamate receptor 5 in the SOD1G93A mouse model of amyotrophic lateral sclerosis. 195
Altered intracellular calcium homeostasis underlying enhanced glutamatergic transmission in striatal-enriched tyrosine phosphatase (STEP) knockout mice 195
In-vivo genetic ablation of metabotropic glutamate receptor type 5 slows down disease progression in the SOD1G93A mouse model of amyotrophic lateral sclerosis 193
CCL5-glutamate interaction in central nervous system: Early and acute presynaptic defects in EAE mice 188
Blockade of stress-induced increase of glutamate release in the rat prefrontal/frontal cortex by agomelatine involves synergy between melatonergic and 5-HT2C receptor-dependent pathways 182
Characterization of the Mitochondrial Aerobic Metabolism in the Pre- and Perisynaptic Districts of the SOD1G93A Mouse Model of Amyotrophic Lateral Sclerosis 180
Altered mechanisms underlying the abnormal glutamate release in amyotrophic lateral sclerosis at a pre-symptomatic stage of the disease 174
Exocytosis regulates trafficking of GABA and glycine heterotransporters in spinal cord glutamatergic synapses: a mechanism for the excessive heterotransporter-induced release of glutamate in experimental amyotrophic lateral sclerosis. 165
Altered Mechanisms Underlying the Abnormal Glutamate Release in Amyotrophic Lateral Sclerosis at a Pre-Symptomatic Stage of the Disease. 165
The endocannabinoid system in rat gliosomes and its role in the modulation of glutamate release 160
Prophylactic versus therapeutic fingolimod: Restoration of presynaptic defects in mice suffering from experimental autoimmune encephalomyelitis 160
Colocalization of neurotransmitter transporters on the plasma membrane of the same nerve terminal may reflect cotransmission. 151
Acute stress rapidly increases the readily releasable pool of glutamate vesicles in prefrontal and frontal cortex through non-genomic action of corticosterone 150
Abnormal exocytotic release of glutamate in a mouse model of amyotrophic lateral sclerosis 149
Chronic mild stress induces anhedonic behavior and changes in glutamate release, BDNF trafficking and dendrite morphology only in stress vulnerable rats. The rapid restorative action of ketamine 148
Enhanced Function and Overexpression of Metabotropic Glutamate Receptors 1 and 5 in the Spinal Cord of the SOD1G93A Mouse Model of Amyotrophic Lateral Sclerosis during Disease Progression 147
Enriched experience and recovery from amblyopia in adult rats: impact of motor, social and sensory components. 146
Functional expression of release-regulating glycine transporters GLYT1 on GABAergic neurons and GLYT2 on astrocytes in mouse spinal cord 144
Mechanisms of glutamate release elicited in rat cerebrocortical nerve endings by ‘pathologically’ elevated extraterminal K+ concentrations 143
The P2X7 receptor as a route for non-exocytotic glutamate release: dependence on the carboxyl tail 142
The high-mobility group box 1 cytokine induces transporter-mediated release of glutamate from glial subcellular particles (gliosomes) prepared from in situ-matured astrocytes 141
Knocking down metabotropic glutamate receptor 1 improves survival and disease progression in the SOD1G93A mouse model of amyotrophic lateral sclerosis 141
Chronic treatment with agomelatine or venlafaxine reduces depolarization-evoked glutamate release from hippocampal synaptosomes 140
Synthesis and evaluation of resins bearing substrate-like inhibitor functions for capturing copper amine oxidases 139
Group I metabotropic glutamate autoreceptors induce abnormal glutamate exocytosis in a mouse model of amyotrophic lateral sclerosis 139
Broad spectrum and prolonged efficacy of dimiracetam in models of neuropathic pain 138
Metabotropic glutamate receptor 5 as a potential target in ALS 135
Abnormal exocytotic release of glutamate in a mouse model of amyotrophic lateral sclerosis. 135
Altered glucose catabolism in the presynaptic and perisynaptic compartments of SOD1G93A mouse spinal cord and motor cortex indicates that mitochondria are the site of bioenergetic imbalance in ALS 135
Sox2 conditional mutation in mouse causes ataxic symptoms, cerebellar vermis hypoplasia, and postnatal defects of Bergmann glia 135
Differential expression of metabotropic glutamate and GABA receptors at neocortical glutamatergic and GABAergic axon terminals 134
Acute Footshock Stress Induces Time-Dependent Modifications of AMPA/NMDA Protein Expression and AMPA Phosphorylation 133
Fluoxetine in adulthood normalizes GABA release and rescues hippocampal synaptic plasticity and spatial memory in a mouse model of Down Syndrome. 132
A New Function for Glycine GLYT2 Transporters: Stimulation of GABA Release from Cerebellar Nerve Terminals Through GAT-1 Transporter Reversal and Ca2+-Dependent Anion Channels 131
Abnormal and precocious exocytotic glutamate release in a mouse model of amyotrophic lateral sclerosis 130
Intravenous Mesenchymal Stem Cells Improve Survival and Motor Function in Experimental Amyotrophic Lateral Sclerosis 129
DIABETIC NEUROPATHIC PAIN: A ROLE FOR TESTOSTERONE METABOLITES 127
Glutamate release from astrocytic gliosomes under physiological and pathological conditions 125
Intravenous mesenchymal stem cells improve survival and motor functions in symptomatic mutant SOD1/G93A mice 125
Role of calpain-1 in the early phase of experimental ALS 124
Unusual increase in lumbar network excitability of the rat spinal cord evoked by the PARP-1 inhibitor PJ-34 through inhibition of glutamate uptake. 123
Neurounina-1, a Novel Compound that Increases Na+/Ca2+ Exchanger Activity, Effectively Protects Against Stroke Damage 123
Stimulation of excitatory amino acid release from adult mouse brain glia subcellular particles by high mobility group box 1 protein 123
Adult astroglia is competent for Na+/Ca2+ exchanger-operated exocytotic glutamate release triggered by mild depolarization 121
Environmental therapy for cognitive and sensory impairment in a mouse model of Down syndrome 121
CCL5-glutamate crosstalk and presynaptic defects in EAE mice 121
Acute stress rapidly increases the readily releasable pool of glutamate vesicles in prefrontal and frontal cortex through non-genomic action of corticosterone. 120
mGluR1 and mGluR5 knock-down improves survival, motor skills and disease progression in amyotrophic lateral sclerosis mouse model 120
Abnormal glutamate release in a mouse model of amyotrophic lateral sclerosis 118
Amyotrophic lateral sclerosis and excitotoxicity: role of Group I metabotropic glutamate receptors 117
Targeting Group I Metabotropic Glutamate Receptors in Amyotrophic Lateral Sclerosis 116
Astrocyte contribution to the excessive glutamate release in the spinal cord of the SOD1G93A mouse model of amyotrophic lateral sclerosis 116
Adaptive modifications in the calpain/calpastatin system in brain cells after persistent alteration in Ca2+ homeostasis 116
Abnormal glutamate release in a mouse model of amyotrophic lateral sclerosis 115
Acute stress and corticosterone increase the readily releasable pool of glutamatergic vesicles in rat synaptosomes of prefrontal/frontal cortex via mineralocorticoid and glucocorticoid receptors 115
Novel phage display-derived neuroblastoma-targeting peptides potentiate the effect of drug nanocarriers in preclinical settings 114
Stress and corticosterone increase the readily releasable pool of glutamate vesicles in synaptic terminals of prefrontal and frontal cortex 114
Agomelatine reduces glutamate release induced by acute stress, possible synergism between melatonin and 5HT2C properties 113
GroupI metabotropic glutamate autoreceptors induce abnormal glutamate exocytosis in a mouse model of amyotrophic lateral sclerosis 113
Group I metabotropic glutamate receptors tune excitotoxicity in amyotrophic lateral sclerosis 113
Effect of miRNAs shuttled by exosomes derived from primed-MSCs on activated-microglia phenotype and possible implication in amyotrophic lateral sclerosis. 112
Synaptic mechanisms underlying the excessive and precocious glutamate release in the spinal cord of sod1g93a mice. 111
GROUP I METABOTROPIC GLUTAMATE RECEPTORS AND NEUROTOXICITY IN AMYOTROPHIC LATERAL SCLEROSIS 111
Knocking-down mGluR1 and mGluR5 in the SOD1/G93A mouse model of amyotrophic lateral sclerosis ameliorates survival and disease progression 111
Increased [3H]D-aspartate release and changes in glutamate receptor expression in the hippocampus of the mnd mouse. 110
In vitro Evidence of Abnormal Glutamate to Glutamine Conversion in Astrocytes harvested from a Mouse Model of Amyotrophic Lateral Sclerosis: a potential Experimental Application of N-13-ammonia 110
Cognitive impairment in Gdi1 deficient mice is associated with altered synaptic vesicle pools and short-term synaptic plasticity, and can be corrected by appropriate learning training 110
The GABAergic-like system in the cyprid of Balanus amphitrite (=Amphibalanus amphitrite) (Cirripedia, Crustacea) 109
Acute ketamine restores deficits in glutamate release and related molecular mechanisms induced by chronic mild stress in vulnerable rats 109
Knocking-down mGlu1 receptors prolongs survival and ameliorates disease progression in the SOD1/G93A mouse model of ALS. 108
Altered Mechanisms Underlying the Abnormal Glutamate Release in Amyotrophic Lateral Sclerosisat a Pre-Symptomatic Stage of the Disease. 108
Abnormal Upregulation of GPR17 Receptor Contributes to Oligodendrocyte Dysfunction in SOD1 G93A Mice 108
Environmental enrichment decreases GABAergic inhibition and improves cognitive abilities, synapticplasticity, and visual functions in a mouse model of Down syndrome 108
Release of [3H]D-aspartate induced by K+-stimulation is increased in the cervical spinal cord of wobbler mice, a model of motor neuron disease. 107
Ketamine modulates glutamate release, BDNF trafficking and dendrite morphology in rats vulnerable to chronic mild stress 107
Gamma-amino butyric acid (GABA) release in the ciliated protozoon Paramecium occurs by neuronal-like exocytosis 105
Proteomic analysis of gliosomes from mouse brain: identification and investigation of glial membrane proteins 105
Impairment of Neuronal Glutamate Uptake and Modulation of the Glutamate Transporter GLT-1 Induced by Retinal Ischemia 105
Altered synaptic mechanisms and excessive glutamate release in amyotrophic lateral sclerosis 102
miRNAs shuttled by exosomes derived from primed-MSCs affect the activated-microglia phenotype and possibly support the therapeutic effects of MSC administration in SOD1G93A mice 101
Abnormal glutamate release induced by group I metabotropic glutamate receptors in experimental ALS. 101
Genetic and pharmacological effects of mGlu5 receptor blockade in the SOD1G93A mouse model of amyotrophic lateral sclerosis 101
In-vivo therapeutic effects of extracellular vesicles derived from mesenchymal stem after systemic administration on ALS mice 100
Exosome-shuttled miRNAs derived from mesenchymal stem cells modulate in-vitro the reactive phenotype of amyotrophic lateral sclerosis glial cells 100
Targeting group i metabotropic glutamate receptors in experimental als. 100
A multistationary loop model of ALS unveils critical molecular interactions involving mitochondria and glucose metabolism 100
Alterations of Synaptic Mechanisms and Excessive Glutamate Release in the Spinal Cord of SOD1G93A Mice 100
Fluoxetine treatment promotes functional recovery in a rat model of cervical spinal cord injury 99
Diabetic neuropathic pain: a role for testosterone metabolites 99
The Modulation of Glutamate Release by Group I Metabotropic Glutamate Auto-Receptors in ALS 99
Acute stress rapidly increases the readily releasable pool of glutamate vesicles in prefrontal and frontal cortex through corticosterone non-genomic action 99
Knocking down mglu1 receptors prolongs survival and improves symptomatology in a mouse model of amyotrophic lateral sclerosis 99
Intravenous mesenchymal stem cells administration induces survival and symptom amelioration in mutant SOD1 G93A mice 99
In-vitro activation of GAT1 transporters expressed in spinal cord gliosomes stimulates glutamate release that is abnormally elevated in the SOd1/G93A(+) mouse model of amyotrophioc lateral sclerosis. 98
Group I metabotropic glutamate receptors in ALS: knocking-down mGlu1 receptors ameliorates survival and disease progression in SOD1/G93A mice. 97
Knocking-down Group I metabotropic glutamate receptors ameliorates survival and disease progression in SOD1G93A mice. 97
Group I metabotropic glutamate receptors modulate glutamate exocytosis in a mouse model of als 97
Non conventional activity of the endocannabinoid system at glutamate release in rat cortical astrocytes 96
Mesemchymal stem cells systemically administered in symptomatic mutant SOD1-G93A mice ameliorate survival and motor abilities 96
Totale 12.542
Salva come PNG Salva come JPEG
Categoria #
all - tutte 67.914
article - articoli 33.088
book - libri 964
conference - conferenze 33.862
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 135.828
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021801 0 0 0 54 83 79 85 117 95 109 82 97
2021/20221.900 37 119 108 191 79 148 123 470 107 173 69 276
2022/20231.838 187 169 23 206 274 289 12 116 295 14 212 41
2023/20241.510 50 175 49 178 124 302 119 67 65 70 108 203
2024/20254.530 218 307 124 307 501 425 384 803 131 200 522 608
2025/20262.282 1.033 242 547 460 0 0 0 0 0 0 0 0
Totale 19.997